[{"indications": "Indications\u00a0 \n(From 14.5.1 Normal immunoglobulin: British National Formulary)\n14.5.1 Normal immunoglobulin", "name": "NORMAL IMMUNOGLOBULIN For intravenous use", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.5 Immunoglobulins", "14.5.1 Normal immunoglobulin", "NORMAL IMMUNOGLOBULIN", "For intravenous use"], "cautions": "Cautions\u00a0hypo- or agammaglobulinaemia with or\r\nwithout IgA deficiency; interference with live virus vaccines\u2014\n(From 14.5.1 Normal immunoglobulin: British National Formulary)\nNormal immunoglobulin may interfere with the immune response to live virus vaccines which should therefore only be given at least 3 weeks before or 3 months after an injection of normal immunoglobulin (this does not apply to yellow fever vaccine since normal immunoglobulin does not contain antibody to this virus).Intravenous use\u00a0thrombophilic disorders, or risk factors for arterial or venous thromboembolic\r\nevents; obesity; ensure adequate hydration, renal insufficiency", "side-effects": "Side-effects\u00a0nausea, diarrhoea, chills, fever, headache, dizziness,\r\narthralgia, myalgia, muscle spasms, low back pain; rarely hypotension, anaphylaxis, cutaneous skin reactions, aseptic meningitis,\r\nacute renal failure; also reported with intravenous use, injection site reactions, abdominal pain and distension, blood\r\npressure fluctuations, haemolytic anaemia, thromboembolic events including\r\nmyocardial infarction, stroke, pulmonary embolism, and deep vein thrombosisNote\u00a0Adverse reactions are more likely to occur\r\nin patients receiving normal immunoglobulin for the first time, or\r\nfollowing a prolonged period between treatments, or when a different\r\nbrand of normal immunoglobulin is administered.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202705.htm", "doses": ["See under preparations", "Antibody titres can vary widely between normal\r\nimmunoglobulin preparations from different manufacturers\u2014formulations\r\nare not interchangeable; patients should be maintained\r\non the same formulation throughout long-term treatment to avoid adverse\r\neffects", "Name[Intratect\u00ae (Biotest UK) ] Intravenous infusion,\r\nhuman normal immunoglobulin (protein 5%), net price 1\u00a0g (20\u00a0mL) =\r\n\u00a345.00, 2.5\u00a0g (50\u00a0mL) = \u00a3112.50, 5\u00a0g (100\u00a0mL) = \u00a3225.00, 10\u00a0g (200\u00a0mL)\r\n= \u00a3450.00, "]}, {"indications": "Indications\u00a0 \n(From 14.5.1 Normal immunoglobulin: British National Formulary)\n14.5.1 Normal immunoglobulin", "name": "NORMAL IMMUNOGLOBULIN For intramuscular use", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.5 Immunoglobulins", "14.5.1 Normal immunoglobulin", "NORMAL IMMUNOGLOBULIN", "For intramuscular use"], "cautions": "Cautions\u00a0hypo- or agammaglobulinaemia with or\r\nwithout IgA deficiency; interference with live virus vaccines\u2014\n(From 14.5.1 Normal immunoglobulin: British National Formulary)\nNormal immunoglobulin may interfere with the immune response to live virus vaccines which should therefore only be given at least 3 weeks before or 3 months after an injection of normal immunoglobulin (this does not apply to yellow fever vaccine since normal immunoglobulin does not contain antibody to this virus).Intravenous use\u00a0thrombophilic disorders, or risk factors for arterial or venous thromboembolic\r\nevents; obesity; ensure adequate hydration, renal insufficiency", "side-effects": "Side-effects\u00a0nausea, diarrhoea, chills, fever, headache, dizziness,\r\narthralgia, myalgia, muscle spasms, low back pain; rarely hypotension, anaphylaxis, cutaneous skin reactions, aseptic meningitis,\r\nacute renal failure; also reported with intravenous use, injection site reactions, abdominal pain and distension, blood\r\npressure fluctuations, haemolytic anaemia, thromboembolic events including\r\nmyocardial infarction, stroke, pulmonary embolism, and deep vein thrombosisNote\u00a0Adverse reactions are more likely to occur\r\nin patients receiving normal immunoglobulin for the first time, or\r\nfollowing a prolonged period between treatments, or when a different\r\nbrand of normal immunoglobulin is administered.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6541.htm", "doses": ["See under preparations", "Antibody titres can vary widely between normal\r\nimmunoglobulin preparations from different manufacturers\u2014formulations\r\nare not interchangeable; patients should be maintained\r\non the same formulation throughout long-term treatment to avoid adverse\r\neffects", "Name[Normal Immunoglobulin ] Normal immunoglobulin injection. 250-mg vial; 750-mg vialDose\u00a0by deep intramuscular injection, to control\r\noutbreaks of hepatitis A (see notes above), 500\u00a0mg; child under 10 years 250\u00a0mg Rubella in pregnancy, prevention of clinical attack, 750\u00a0mgAvailable from the Centre for Infections and other regional\r\nHealth Protection Agency offices (for contacts and control of outbreaks\r\nonly, see section 14.5 under Availability)"]}, {"indications": "Indications\u00a0 \n(From 14.5.1 Normal immunoglobulin: British National Formulary)\n14.5.1 Normal immunoglobulin", "name": "NORMAL IMMUNOGLOBULIN For subcutaneous use", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.5 Immunoglobulins", "14.5.1 Normal immunoglobulin", "NORMAL IMMUNOGLOBULIN", "For subcutaneous use"], "cautions": "Cautions\u00a0hypo- or agammaglobulinaemia with or\r\nwithout IgA deficiency; interference with live virus vaccines\u2014\n(From 14.5.1 Normal immunoglobulin: British National Formulary)\nNormal immunoglobulin may interfere with the immune response to live virus vaccines which should therefore only be given at least 3 weeks before or 3 months after an injection of normal immunoglobulin (this does not apply to yellow fever vaccine since normal immunoglobulin does not contain antibody to this virus).Intravenous use\u00a0thrombophilic disorders, or risk factors for arterial or venous thromboembolic\r\nevents; obesity; ensure adequate hydration, renal insufficiency", "side-effects": "Side-effects\u00a0nausea, diarrhoea, chills, fever, headache, dizziness,\r\narthralgia, myalgia, muscle spasms, low back pain; rarely hypotension, anaphylaxis, cutaneous skin reactions, aseptic meningitis,\r\nacute renal failure; also reported with intravenous use, injection site reactions, abdominal pain and distension, blood\r\npressure fluctuations, haemolytic anaemia, thromboembolic events including\r\nmyocardial infarction, stroke, pulmonary embolism, and deep vein thrombosisNote\u00a0Adverse reactions are more likely to occur\r\nin patients receiving normal immunoglobulin for the first time, or\r\nfollowing a prolonged period between treatments, or when a different\r\nbrand of normal immunoglobulin is administered.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129009.htm", "doses": ["See under preparations", "Antibody titres can vary widely between normal\r\nimmunoglobulin preparations from different manufacturers\u2014formulations\r\nare not interchangeable; patients should be maintained\r\non the same formulation throughout long-term treatment to avoid adverse\r\neffects", "By intramuscular injection, Hepatitis A prophylaxis\r\nin outbreaks (see notes above), adult and child over\r\n10 years, 750\u00a0mg, child under 10 years,\r\n500\u00a0mg", "Subgam\u00ae is not licensed\r\nfor prophylactic use, but due to difficulty in obtaining suitable\r\nimmunoglobulin products, the Health Protection Agency recommends intramuscular\r\nuse for prophylaxis against Hepatitis A or rubella", "Name[Subgam\u00ae (BPL) ] Normal immunoglobulin (protein 14%-18%) injection, net price 250-mg\r\nvial = \u00a311.20, 750-mg vial = \u00a328.50, 1.5-g vial = \u00a357.00Dose\u00a0by subcutaneous infusion,\r\nantibody deficiency syndromes, consult product literatureBy intramuscular injection, Hepatitis A prophylaxis\r\nin outbreaks (see notes above), adult and child over\r\n10 years, 750\u00a0mg, child under 10 years,\r\n500\u00a0mgRubella, in pregnancy, prevention of clinical attack (see also notes above), 750\u00a0mg Note\u00a0Subgam\u00ae is not licensed\r\nfor prophylactic use, but due to difficulty in obtaining suitable\r\nimmunoglobulin products, the Health Protection Agency recommends intramuscular\r\nuse for prophylaxis against Hepatitis A or rubella"]}, {"indications": "Indications\u00a0 \n(From 14.5.1 Normal immunoglobulin: British National Formulary)\n14.5.1 Normal immunoglobulin", "name": "NORMAL IMMUNOGLOBULIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.5 Immunoglobulins", "14.5.1 Normal immunoglobulin", "NORMAL IMMUNOGLOBULIN"], "cautions": "Cautions\u00a0hypo- or agammaglobulinaemia with or\r\nwithout IgA deficiency; interference with live virus vaccines\u2014\n(From 14.5.1 Normal immunoglobulin: British National Formulary)\nNormal immunoglobulin may interfere with the immune response to live virus vaccines which should therefore only be given at least 3 weeks before or 3 months after an injection of normal immunoglobulin (this does not apply to yellow fever vaccine since normal immunoglobulin does not contain antibody to this virus).Intravenous use\u00a0thrombophilic disorders, or risk factors for arterial or venous thromboembolic\r\nevents; obesity; ensure adequate hydration, renal insufficiency", "side-effects": "Side-effects\u00a0nausea, diarrhoea, chills, fever, headache, dizziness,\r\narthralgia, myalgia, muscle spasms, low back pain; rarely hypotension, anaphylaxis, cutaneous skin reactions, aseptic meningitis,\r\nacute renal failure; also reported with intravenous use, injection site reactions, abdominal pain and distension, blood\r\npressure fluctuations, haemolytic anaemia, thromboembolic events including\r\nmyocardial infarction, stroke, pulmonary embolism, and deep vein thrombosisNote\u00a0Adverse reactions are more likely to occur\r\nin patients receiving normal immunoglobulin for the first time, or\r\nfollowing a prolonged period between treatments, or when a different\r\nbrand of normal immunoglobulin is administered.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128177.htm", "doses": ["See under preparations", "Antibody titres can vary widely between normal\r\nimmunoglobulin preparations from different manufacturers\u2014formulations\r\nare not interchangeable; patients should be maintained\r\non the same formulation throughout long-term treatment to avoid adverse\r\neffects"]}]